Stock HROW HARROW, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
18.17 USD +1.17% Intraday chart for Harrow, Inc. +1.23% +62.23%
Jun. 05 Harrow, Inc. Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study CI
Jun. 03 Lake Street Raises Price Target on Harrow to $25 From $20, Maintains Buy Rating MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HARROW, INC. Stock Harrow, Inc.
+62.23% 643M
C-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.62% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-2.04% 219B
A+
NOVARTIS AG Stock Novartis AG
+10.95% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.73% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. HROW Stock
  4. Ratings Harrow, Inc.